Compound 10 slowed hallmark Alzheimer’s damage in mice, reducing nerve-cell death and extending survival in ETH Zurich experiments published in Cell Reports Medicine.
GRK2 drove the work: researchers found its inactive form accumulates in dementia brains, clogs mitochondrial pores, cuts cellular energy and fuels more amyloid beta in a self-reinforcing cycle.
In mouse and cell tests, Compound 10 blocked GRK2 aggregation, improved mitochondrial function, lowered amyloid buildup and preserved neuron function; the team also saw better heart function and fewer grey hairs.
ETH Zurich has patented the compound and is seeking a company to advance it toward a drug, arguing the GRK2 pathway offers a mechanism distinct from current medicines that only delay decline by several months.
A potential Alzheimer's drug also reverses aging in mice. Could it unlock human longevity?
Could targeting cellular 'power plants' finally be the key to defeating Alzheimer's disease?
ETH Zurich’s Compound 10 Offers Breakthrough Preclinical Results in Alzheimer’s Disease by Targeting Mitochondrial Dysfunction
Overview
ETH Zurich has discovered Compound 10, a new compound that offers a promising and unique approach to treating Alzheimer's disease. Unlike traditional therapies that focus on removing protein deposits like amyloid plaques, Compound 10 works by protecting brain cells from stress and energy failure. This new mechanism could be crucial for slowing disease progression and preserving neuronal function. By opening the door to a fresh treatment strategy, Compound 10 brings hope to patients who currently have limited options, marking an important step forward in the search for effective Alzheimer's therapies.